This article is a correction to:
Dose reduction of biologics in patients with plaque psoriasis: a review
C. A. M. van Riel1,2*
C. A. J. Michielsens1,2M. E. van Muijen3,4L. S. van der Schoot1,2J. M. P. A. van den Reek1,2E. M. G. J. de Jong1,2,5- 1Radboud University Medical Centre, Nijmegen, Netherlands
- 2Department of Dermatology, Radboud University Medical Centre, Nijmegen, Gelderland, Netherlands
- 3Maastricht University Medical Centre, Maastricht, Limburg, Netherlands
- 4Department of Dermatology, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, Netherlands, Netherlands
- 5Radboud University, Nijmegen, Gelderland, Netherlands
A Corrigendum on
Dose reduction of biologics in patients with plaque psoriasis: a review
by van Riel CAM, Michielsens CAJ, van Muijen ME, van der Schoot LS, van den Reek JMPA and de Jong EMGJ (2024). Front. Pharmacol. 15:1369805. doi: 10.3389/fphar.2024.1369805
In the published article, there was an error. The symbol ‘≤’, in the phrase “[…] biologic use for ≤6 months […]” is incorrect. This should be the symbol ‘≥’.
A correction has been made to the Discussion, Paragraph 1. This sentence previously stated:
“Considering the studies on DR strategies, the eligibility criteria for DR mainly included biologic use for ≤6 months, a stable low disease activity from ≥6 months to ≥1 year, determined by an absolute or relative PASI (PASI ≤3/≤5/PASI 75–100) and/or DLQI ≤3/≤5, or BSA ≤1/≤2, or PGA ≤1/0-2 during a period ranging from 12 weeks to ≥1 year (Atalay et al., 2021; Aubert et al., 2022; Atalay et al., 2022b; van der Schoot et al., 2022b; Di Altobrando et al., 2022; van Muijen et al., 2022; Herranz-Pinto et al., 2023).”
The corrected sentence appears below:
“Considering the studies on DR strategies, the eligibility criteria for DR mainly included biologic use for ≥6 months, a stable low disease activity from ≥6 months to ≥1 year, determined by an absolute or relative PASI (PASI ≤3/≤5/PASI 75–100) and/or DLQI ≤3/≤5, or BSA ≤1/≤2, or PGA ≤1/0-2 during a period ranging from 12 weeks to ≥1 year (Atalay et al., 2021; Aubert et al., 2022; Atalay et al., 2022b; van der Schoot et al., 2022b; Di Altobrando et al., 2022; van Muijen et al., 2022; Herranz-Pinto et al., 2023).”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: psoriasis, dose reduction, dose tapering, clinical practice, implementation, biologics, biologicals, (cost-)effectiveness
Citation: van Riel CAM, Michielsens CAJ, van Muijen ME, van der Schoot LS, van den Reek JMPA and de Jong EMGJ (2024) Corrigendum: Dose reduction of biologics in patients with plaque psoriasis: a review. Front. Pharmacol. 15:1505626. doi: 10.3389/fphar.2024.1505626
Received: 03 October 2024; Accepted: 07 October 2024;
Published: 14 October 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 van Riel, Michielsens, van Muijen, van der Schoot, van den Reek and de Jong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: C. A. M. van Riel, charlotte.vanriel@radboudumc.nl